BridgeBio Oncology Therapeutics, Inc. (BBOT) — Stock Score Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) has a MoatMap StockRank of 11/100 based on Quality (38/100), Value (39/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. A pre-revenue clinical-stage oncology biotech. While the science may be promising, it is highly speculative and lacks the business model durability, cash flows, and moats required for our concentrated fund.

BridgeBio Oncology Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for genetically-driven cancers. Leveraging a precision medicine approach, the company focuses on specific mutations and molecular pathways to address unmet needs in oncology. It operates as a specialized subsidiary within the broader BridgeBio Pharma ecosystem, aiming to bring innovative cancer treatments from discovery to patients.

Key Financial Metrics

Price$7.26
Market Cap$708M
P/E (Forward)-3.84
Price/Book1.77
Return on Equity-62.2%
Return on Invested Capital-35.3%
Debt/Equity0.71
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-86M

BridgeBio Oncology Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BridgeBio Oncology Therapeutics, Inc.’s (BBOT) StockRank?
MoatMap’s StockRank for BridgeBio Oncology Therapeutics, Inc. (BBOT) is 11/100, with a Strong Sell signal. It is a composite of Quality (38), Value (39), and Momentum (17) factor ranks across MoatMap’s 19,000+ stock universe.
Does BridgeBio Oncology Therapeutics, Inc. have an economic moat?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BridgeBio Oncology Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for BridgeBio Oncology Therapeutics, Inc. (BBOT) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BridgeBio Oncology Therapeutics, Inc. in?
BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBBOT deep dive reportAI ChampionsHow we score stocksSense-check another stock